We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Metavention

News List

Metavention Completes U.S. Enrollment in Groundbreaking Feasibility Study to Treat Type 2 Diabetes prnasia
January 06, 2022
Metavention, Inc. announces the completion of enrollment in the DeLIVER U.S. Study (NCT04285554), to evaluate the safety of sympathetic denervation of the liver using its new Integrated Radio Frequency (iRF) Denervation System.
Metavention Initiates Trial for Novel Treatment of Type 2 Diabetes americanpharmaceuticalreview
February 20, 2021
Metavention announced the initiation of an U.S. Food and Drug Administration (FDA) approved clinical investigation, DeLIVER, for the Company's intravascular iRF Denervation System to determine safety in patients with type 2 diabetes (T2D).